

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Tislelizumab	anti-PD-1	1L NonSq SCLC, 1L Sq. NSCLC, 2/3L NSCLC				China
		1L GC/GEJC				China
		1L PD-L1 positive ESCC				China
		2L ESCC				US, China, Europe
		1L NPC, 1L ES-SCLC, 1L HCC				China
		1L UBC, LA ESCC, Neo/adj NSCLC*				
		Neoadj MSI-H or dMMR CRC				
		Resectable ESCC				
		NSCLC				
Ociperlimab	anti-TIGIT	1L PD-L1 high NSCLC				
		1L NSCLC				
		2L+ PD-L1 positive ESCC				
		1L HCC				
		Solid Tumors				
		1L LS-SCLC				
		2/3L cervical cancer				

Safety and efficacy have not been established for investigational products and/or uses.

CRC, colorectal cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; 1L, first line; LA, locally advanced; MSI-H, microsatellite instability-high; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; UBC, urothelial bladder cancer.

*Primary endpoint met.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
LBL-007*	anti-LAG-3	MSS-CRC				
		1L ESCC				
Surzebiclimab	anti-TIM-3	Solid Tumors				
Zanidatamab†	anti-HER2 BsAb	HER2+ 2L BTC				
		1L HER2+ GEA				
		1L HER2+ mBC/GC				
BGB-A445	anti-OX40	Melanoma, RCC, UC				
		Solid Tumors				
BGB-15025 / 26808	HPK1 inhibitor	Solid Tumors				
BGB-24714	SMAC mimetic	Solid tumors				
BGB-43395	CDK4 inhibitor	BC & Solid tumors				
BGB-3245	BRAF	GI & Solid Tumors				
BGB-B167	CEA-4-1BB BsAB	Solid Tumors				

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; BRAF, v-raf murine sarcoma viral oncogene homolog B; CDK4, cyclin-dependent kinase 4; CEA-4-1BB, carcinoembryonic antigen-specific 4-1BB; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; HPK1, hematopoietic progenitor kinase 1; 2L, second line; LAG-3, lymphocyte activation gene 3 protein; mBC, metastatic breast cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also known as CD134; RCC, renal cell carcinoma; SMAC, second mitochondria-derived activator of caspase; UC, urothelial carcinoma.

*Leads Biolabs collaboration, BeiGene has ex-China commercial rights.

†Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-30813	DGKζ inhibitor	Solid tumors				
BGB-A3055	anti-CCR8	Solid tumors				
BGB-10188	PI3Kδ inhibitor	Solid tumors				
Pamiparib	PARP 1/2 inhibitor	2L MTx gBRCAm PSOC				
		Advanced ovarian cancer				China
Tarlatamab*	DLL3 x CD3	2L SCLC				
Xaluritamig*	STEAP1 x CD3	mCRPC (initiation activities)				
Lifirafenib†	RAF inhibitor	Solid tumors				
Lenvatinib	tyrosine kinase inhibitor	Solid tumors				
		1L HCC				
Surufatinib‡	VEGFR, FGFR, CSF-1R inhibitor	Solid tumors				
Fruquintinib‡	VEGFR inhibitor	GC/GEJC and CRC				
		00US3-TNBC/CRC/endometrial				
DKN-01§	anti-DKK1	GC/GEJC				
Sitravatinib¶	multikinase inhibitor	NSCLC post PD-(L)1 therapy				
		ESCC post PD-(L)1 therapy				

Safety and efficacy have not been established for investigational products and/or uses.

TNBC, triple-negative breast cancer; CCR8, CC chemokine receptor 8; CD3, cluster of differentiation 3; CRC, colorectal cancer; CSF-1R, colony-stimulating factor-1 receptor; DGKζ, diacylglycerol kinase ζ; DKK1, dickkopf-1; DLL3, delta-like ligand 3; ESCC, esophageal squamous cell carcinoma; FGFR, fibroblast growth factor receptor; gBRCAm, germline BRCA mutation; GC-GEJC, gastric cancer-gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; 1L, first line; mCRPC, metastatic castration-resistant prostate cancer; MTx, maintenance treatment; NSCLC, non-small cell lung cancer; PARP, poly(ADP-ribose) polymerase; PI3Kδ, phosphoinositide 3-kinase delta; PSOC, platinum-sensitive ovarian cancer; RAF, rapidly accelerated fibrosarcoma; STEAP1, Six-Transmembrane Epithelial Antigen of the Prostate 1; VEGFR, vascular endothelial growth factor receptors.

*Amgen collaboration, BeiGene has China commercial rights.

†In collaboration with SpringWorks Therapeutics, Inc.

‡Clinical collaboration with Hutchison Medipharma International.

§In collaboration with Leap Therapeutics, Inc.

¶Partnership with Mirati Therapeutics, Inc.